
Amgen Reports 6% Revenue Growth to $8.6 Billion Driven by 9% Volume Surge
Amgen Inc.Description
What this story covers
Amgen’s Q1 2026 results show a 6% revenue increase to $8.6 billion, fueled by strong volume growth in new oncology and rare disease therapies. Despite pricing pressures and mature product erosion, the company reaffirmed confident full-year earnings guidance.
Story snapshot
CompanyAmgen Inc.
TickerAMGN
VariantStandard detailed
Duration6:47
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000318154-26-000054
Sources1
Full Story Script
Content not available for this story.